BioSpace News Archive

LAV211 bio-stimulant advancing towards anticipated 2022 commercial launch in spring wheat; Product advancement achieved in multiple programs

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft ti

The growing clinical acceptance of drug-free alternatives to painkiller pharmaceuticals among the general population is a key driver for the evolution in the pain management devices market.

Ophthalmic refractometer is an equipment which is used for measuring lens strength and power, in order to provide patients with proper eyeglasses for correcting their vision.

The global medical equipment maintenance market is expected to grow at promising pace during the assessment period 2019–2029.

Biopsies have remarkably advanced the molecular medicine in general and oncology in particular. Technological strides in the devices used for biopsies have considerably improved the molecular characterization of cancers.

Most sterilization processing departments have steam sterilizers, dry heat sterilization, chemical sterilization, and plasma gas sterilizers.

The acute myeloid leukemia biomarker testing market is anticipated to gain promising growth across the tenure of 2020-2030.

Scopus BioPharma Inc. announced the appointment of additional members to its Board of Directors.

NanOlogy, LLC, a clinical-stage oncology company, announced that results from its Phase 1/2 clinical trial of SOR007 in the treatment of cutaneous metastases were presented during the 2020 San Antonio Breast Cancer Symposium by Mario Lacouture, MD, Director of Oncodermatology, Memorial Sloan Kettering Cancer Center.